RT Journal Article
SR Electronic
T1 Discriminative Subtyping of Lung Cancers from Histopathology Images via Contextual Deep Learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.25.20140053
DO 10.1101/2020.06.25.20140053
A1 Benjamin J. Lengerich
A1 Maruan Al-Shedivat
A1 Amir Alavi
A1 Jennifer Williams
A1 Sami Labbaki
A1 Eric P. Xing
YR 2020
UL http://medrxiv.org/content/early/2020/06/26/2020.06.25.20140053.abstract
AB When designing individualized treatment protocols for cancer patients, clinicians must synthesize the information from multiple data modalities into a single parsimonious description of the patient’s personal disease. However, such a description of a patient is never observed. In this work, we propose to model these patient descriptions as latent discriminative subtypes—sample representations which can be learned from one data modality and used to contextualize predictions based on another data modality. We apply contextual deep learning to learn these sample-specific discriminative subtypes from lung cancer histopathology imagery. Based on these subtypes, we produce sample-specific transcriptomic models which accurately classify samples as adenocarcinoma, squamous cell carcinoma, or healthy tissue (F1 score of 0.97, outperforming previous state-of-the-art multimodal approaches). Combining these data modalities in a single pipeline not only improves the predictive accuracy, but also gives biological interpretations of the discriminative subtypes and ties the phenotypic patterns present in histopathology images to biological processes.Competing Interest StatementEX is a founder of Petuum, Inc.Funding StatementThis work was supported in part by NIH R01GM114311. B.L. was supported in part by the CMLH Fellowship. M.A. was supported in part by the Google PhD Fellowship. A.A. was supported in part NIH grants 1R01GM122096 and OT2OD026682. J.W. was supported by NIH T32 training grant T32 EB009403 as part of the HHMI-NIBIB Interfaces Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTCGA data is publicly available at the following link. https://portal.gdc.cancer.gov/